公开(公告)号：WO2012098416A1

公开(公告)日：2012-07-26

申请号：PCT/GB2012/050132

申请日：2012-01-23

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD ,  SENGUPTA, Prabal ,  CHOKSHI, Hemant Ashvinbhai ,  PURI, Chetan Surjitsingh ,  CHIMANWALA, Sabbirhusen Yusufbhai ,  MEHTA, Varun Anilkumar ,  DESAI, Dipali Manubhai ,  CHITTURI, Trinadha Rao ,  THENNATI, Rajamannar ,  ATKINSON, Jonathan David Mark

Inventor： SENGUPTA, Prabal ,  CHOKSHI, Hemant Ashvinbhai ,  PURI, Chetan Surjitsingh ,  CHIMANWALA, Sabbirhusen Yusufbhai ,  MEHTA, Varun Anilkumar ,  DESAI, Dipali Manubhai ,  CHITTURI, Trinadha Rao ,  THENNATI, Rajamannar ,  ATKINSON, Jonathan David Mark

IPC: C07D213/16 ,  C07D215/04 ,  C07D277/64 ,  C07D401/06 ,  C07D401/12 ,  C07D417/06 ,  C07D471/00 ,  C07D487/00 ,  A61K31/4188 ,  A61K31/428 ,  A61K31/4353 ,  A61K31/4406 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4965

CPC classification number: C07D241/40 ,  C07C243/38 ,  C07D213/56 ,  C07D215/12 ,  C07D215/14 ,  C07D231/12 ,  C07D239/74 ,  C07D277/64 ,  C07D401/06 ,  C07D401/12 ,  C07D409/06 ,  C07D417/06 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention relates to novel diarylacetylene hydrazide compounds of formula (I) or pharmaceutically acceptable salt thereof, as tyrosine kinase inhibitors, the process for their preparation, and to the use of the compounds of formula (I) in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to tyrosine kinases, in warm-blooded animals

Abstract translation: 本发明涉及式（I）的新型二芳基乙炔酰肼化合物或其药学上可接受的盐作为酪氨酸激酶抑制剂，其制备方法以及式（I）化合物在制备药物组合物中的用途 在温血动物中治疗与酪氨酸激酶相关的疾病

公开(公告)号：WO2011145109A1

公开(公告)日：2011-11-24

申请号：PCT/IN2011/000337

申请日：2011-05-13

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD., ,  BHOWMICK, Subhas ,  KANE, Prashant ,  S, Ganesh ,  PATEL, Tarun ,  CHUDIWAL, Swapnil

Inventor： BHOWMICK, Subhas ,  KANE, Prashant ,  S, Ganesh ,  PATEL, Tarun ,  CHUDIWAL, Swapnil

IPC: A61K9/00 ,  A61K31/137

CPC classification number: A61K31/137 ,  A61K9/0075 ,  A61K9/145

Abstract: The dry powder inhalation composition comprising: (1) salmeterol xinafoate having mean particle size in range of 2.0 μ - 6 μ microns and a tapped density in the range of 0.20 g.com -3 to 0.45 g.com -3 and (2) optionally, one or more other active ingredients and pharmaceutically acceptable carrier.

Abstract translation: 所述干粉吸入组合物包含：（1）平均粒度在2.0微米-6微米范围内的轻度密度和0.20g.com -3至0.45g.com -3和（2）范围内的敲击密度的沙美特罗昔萘酸盐， 任选地，一种或多种其它活性成分和药学上可接受的载体。

公开(公告)号：WO2008111096A2

公开(公告)日：2008-09-18

申请号：PCT/IN2008/000147

申请日：2008-03-14

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD ,  THENNATI, Rajamannar ,  SAMANTA, Biswajit ,  PAL, Ranjan Kumar ,  KILARU, Srinivasu ,  JIVANI, Jignesh ,  KUMBHANI, Savajibhai Anil ,  ADHYAPAK, Jay Prakashchandra

Inventor： THENNATI, Rajamannar ,  SAMANTA, Biswajit ,  PAL, Ranjan Kumar ,  KILARU, Srinivasu ,  JIVANI, Jignesh ,  KUMBHANI, Savajibhai Anil ,  ADHYAPAK, Jay Prakashchandra

IPC: C07C251/60

CPC classification number: C07C271/60 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07D211/34 ,  C07D277/40 ,  C07D295/185 ,  C07D401/12

Abstract: The present invention describes novel prodrugs of formula (I) or their salts, process of preparation and uses thereof.

Abstract translation: 本发明描述了式（I）的新型前药或其盐，其制备方法和用途。

公开(公告)号：WO2020250133A1

公开(公告)日：2020-12-17

申请号：PCT/IB2020/055425

申请日：2020-06-09

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

Inventor： DAMLE, Nitin Krishnaji ,  GOLDFINE, Andrew Michael ,  MANDHANE, Sanjaykumar Nandlal

IPC: A61K31/47 ,  A61P25/16 ,  A61P25/28

Abstract: A method of treating or preventing synucleinopathies in a human subject comprising administering a therapeutically effective amount of a compound of Formula 1 or its pharmaceutically acceptable salt.

公开(公告)号：WO2017037742A1

公开(公告)日：2017-03-09

申请号：PCT/IN2016/050289

申请日：2016-09-01

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

Inventor： DHARMADHIKARI, Nitin Bhalachandra ,  ZALA, Yashoraj Rupsinh ,  VENKATA, Rama Rao Kamala

IPC: A61K31/433

CPC classification number: A61K31/433 ,  A61K9/0004

Abstract: An oral pharmaceutical composition comprising tizanidine or pharmaceutically acceptable salts thereof, as the sole active ingredient in admixture with a release modifying agent wherein the release modifying agent comprises atleast one release modifying hydrophobic non-polymeric material, and wherein the bioavailability of tizanidine or the pharmaceutically acceptable salt thereof is not affected by the presence or absence of food in a subject's gastrointestinal tract.

Abstract translation: 一种口服药物组合物，其包含替扎尼定或其药学上可接受的盐作为与释放调节剂混合的唯一活性成分，其中所述释放调节剂包含至少一种释放改性疏水性非聚合物质，并且其中所述替扎尼定或其药学上可接受的生物利用度 其盐不受受试者的胃肠道中食物的存在或不存在的影响。

公开(公告)号：WO2016135753A1

公开(公告)日：2016-09-01

申请号：PCT/IN2016/050067

申请日：2016-02-25

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

Inventor： BOMMAGANI, Madhusudhan ,  BHOWMICK, Subhas Balaram ,  KANE, Prashant ,  DUBEY, Vaibhav

IPC: A61K9/00 ,  A61K9/06 ,  A61K9/12 ,  A61K9/51 ,  A61K31/65

CPC classification number: A61K31/65 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/122 ,  A61K9/146

Abstract: The present invention relates to a method of preparing a nanoparticulate topical composition of a water soluble, water-susceptible active ingredient or its pharmaceutically acceptable salt, the method comprising steps of milling the water soluble, water-susceptible active ingredient or its salt, a wetting agent and a non-aqueous liquid vehicle to obtain a non-aqueous nanosuspension and converting the non-aqueous nanosuspension into a topical composition.

Abstract translation: 本发明涉及一种制备水溶性，水敏感性活性成分或其药学上可接受的盐的纳米颗粒局部组合物的方法，所述方法包括以下步骤：研磨水溶性，水敏感的活性成分或其盐，润湿 试剂和非水液体载体以获得非水性纳米悬浮液并将非水性纳米悬浮液转化成局部组合物。

公开(公告)号：WO2013093931A2

公开(公告)日：2013-06-27

申请号：PCT/IN2012/000590

申请日：2012-09-06

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD. ,  PATEL, Jiten Ranchhodbhai ,  PATEL, Gopalkumar Chimanlal ,  SHETH, Gaurav Sanjivkumar ,  MANDHANE, Sanjay Nandlalji ,  CHITTURI, Trinadha Rao ,  THENNATI, Rajamannar

Inventor： PATEL, Jiten Ranchhodbhai ,  PATEL, Gopalkumar Chimanlal ,  SHETH, Gaurav Sanjivkumar ,  MANDHANE, Sanjay Nandlalji ,  CHITTURI, Trinadha Rao ,  THENNATI, Rajamannar

CPC classification number: C07D489/04 ,  C07D295/32 ,  C07D491/22

Abstract: The present invention relates to novel hydrazide group containing carbamate prodrugs of phenolic drugs of formula (I) or pharmaceutically acceptable salt thereof, and process for the preparation thereof.

Abstract translation: 本发明涉及式（I）的酚类药物或其药学上可接受的盐的新的含酰肼基团的氨基甲酸酯前体药物及其制备方法。

公开(公告)号：WO2012131722A1

公开(公告)日：2012-10-04

申请号：PCT/IN2012/000218

申请日：2012-03-29

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD. ,  DHARMADHIKARI, Nitin Bhalachandra ,  ZALA, Yashoraj Rupsinh ,  JAISWAL, Sunil Beharilal

Inventor： DHARMADHIKARI, Nitin Bhalachandra ,  ZALA, Yashoraj Rupsinh ,  JAISWAL, Sunil Beharilal

IPC: A61K9/20 ,  A61K31/4402 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38

CPC classification number: A61K9/2077 ,  A61K9/2027 ,  A61K9/2086 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/4402

Abstract: The present invention provides a controlled release dosage form comprising a mixture of betahistine or its pharmaceutically acceptable salt complexed with ion exchange resin with one or more gel forming polymer. Further, in preferred aspect, the present invention provides a controlled release solid dosage form comprising " a controlled release composition comprising betahistine or its pharmaceutically acceptable salt, one or more gel forming polymers and pharmaceutically acceptable excipients; " an immediate release composition comprising betahistine or its pharmaceutically acceptable salt wherein the solid dosage form is suitable for once a day administration.

Abstract translation: 本发明提供了一种控释剂型，其包含与一种或多种形成凝胶的聚合物与离子交换树脂络合的双马来西亚或其药学上可接受的盐的混合物。 此外，在优选的方面，本发明提供了一种控释固体剂型，其包含“包含betahistine或其药学上可接受的盐，一种或多种凝胶形成聚合物和药学上可接受的赋形剂的控释组合物;”速释组合物，其包含betahistine或其 药学上可接受的盐，其中固体剂型适合于一天一次给药。

公开(公告)号：WO2012085937A1

公开(公告)日：2012-06-28

申请号：PCT/IN2011/000872

申请日：2011-12-20

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD. ,  KANE, Prashant ,  GOKHALE, Satish Madhukar ,  GOLE, Nachiket

Inventor： KANE, Prashant ,  GOKHALE, Satish Madhukar ,  GOLE, Nachiket

IPC: B65D83/76

CPC classification number: B65D83/0072

Abstract: The present invention describes a device suitable for dispensing multiple doses of a liquid medicament, the device comprising a) a container having a liquid medicament therein, comprising at least one collapsible wall (3) b) a rotating plunger (7) connected to a push button (8) and c) locking means wherein upon pressing the push button (8), the rotating plunger (7) rotates and traverses from the first position to a traversed position causing preset compression of the collapsible wall of the container (3) to dispense a preset volume of the liquid medicament, and wherein the rotating plunger (7) is locked from returning to the first position by the locking means, thereby preventing air from entering back into the container to maintain a sterile environment within the container (3).

Abstract translation: 本发明描述了一种适于分配多剂量液体药物的装置，该装置包括a）在其中具有液体药物的容器，包括至少一个可折叠壁（3），b）连接到推动件的旋转柱塞（7） 按钮（8）和c）锁定装置，其中在按压按钮（8）时，旋转柱塞（7）从第一位置旋转并且从第一位置移动到穿过位置，从而使容器（3）的可折叠壁的预设压缩 分配液体药物的预设体积，并且其中旋转柱塞（7）通过锁定装置被锁定以返回到第一位置，从而防止空气返回到容器中以将无菌环境保持在容器（3）内， 。

公开(公告)号：WO2012029076A2

公开(公告)日：2012-03-08

申请号：PCT/IN2011/000594

申请日：2011-08-30

Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD. ,  KHOPADE, Ajay Jaysingh ,  ARULSUDAR, N ,  BHOWMICK, Subhas Balaram ,  BOROLE, Bhushan Shrikant

Inventor： KHOPADE, Ajay Jaysingh ,  ARULSUDAR, N ,  BHOWMICK, Subhas Balaram ,  BOROLE, Bhushan Shrikant

IPC: A61K9/10

CPC classification number: A61K9/0019 ,  A61K9/08 ,  A61K9/10

Abstract: A pharmaceutical composition in the form of a solution comprising water insoluble therapeutically active ingredient and a close structural analog of the water insoluble active ingredient, one or more pharmaceutically acceptable excipients and one or more water miscible solvents wherein the water insoluble active ingredient is present in therapeutically effective amounts and the close structural analog is present in sufficient amounts such that when the composition is added to an aqueous vehicle it forms a nanodispersion suitable for intravenous infusion wherein said nanodispersion is stable for longer periods as compared to a dispersion formed from an identical composition but devoid of the close structural analog of the water insoluble active ingredient.

Abstract translation: 包含水不溶性治疗活性成分和水不溶性活性成分的紧密结构类似物，一种或多种药学上可接受的赋形剂和一种或多种水混溶性溶剂的溶液形式的药物组合物，其中 水不溶性活性成分以治疗有效量存在，并且紧密结构类似物以足够的量存在，使得当组合物加入含水载体中时，其形成适于静脉内输注的纳米分散体，其中所述纳米分散体与 由相同组合物形成但不含水不溶性活性成分的密切结构类似物的分散体。